To determine whether or not GRP78 CAR-T cells could be used to treat AML, Nikhil Hebbar et al. conducted in vitro and in vivo tests, finding that the CAR-T cells successfully recognized and eradicated GRP78+ AML, but HSPCs did not elicit a substantial toxic response [117]. The gene discussed is HSPA5; the disease is acute myeloid leukemia.